

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weitz

Serial No: 10/019,325

Filed: December 21, 2001

For: Heparin Compositions that Inhibit Clot Associated Coagulation Factors Art Unit: Not yet assigned

Attorney Document No.: GDV-001.01

### CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231, on May 3, 2002.

## RESPONSE TO NOTICE OF MISSING REQUIREMENTS

Box Missing Parts Commissioner for Patents and Trademarks Washington, DC 20231

Sir:

In response to the Notice of Missing Requirements dated March 8, 2002, Applicants submit herewith a check totaling \$130.00. Also enclosed is a copy of the executed declaration that we filed on February 11, 2002; a copy of the stamped postcard showing that the declaration was received at the PTO on February 27, 2002; and a copy of the Notice of Missing Requirements.

The Notice also requires a copy of the "Sequence Listing" in computer readable form. Applicants respectfully submit that this application does not require submission of a Sequence Listing, under C.F.R. 1.821(e) only applications which contain disclosures of nucleotide and/or amino acid sequences require a copy of the sequence listing. This application does not contain disclosures of nucleotide and/or amino acid sequences. Accordingly, there is no sequence to submit.

Although we believe that we have submitted the correct amount to cover the above-listed items, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our Deposit Account No. 06-1448.

Respectfully Submitted,

Anita Varma Reg. No. 43,221

Date: May 3, 2002

Customer No: 25181
Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109-2170

, MA 02109-2170

00/20/2002 MALIST 00000090 10019325

OS FERRES

130.00 CP



Appln. Serial No. 10/019,325 Filed: December 21, 2001

Atty Docket No.: <u>GDV-001.01</u>
(|\$403 - 101)

Applicants: Jeffrey I. Weitz

Heparin Compositions That Inhibit Clot Associated Coagulation Factors Title:

The following was/were received in the U.S. Patent & Trademark Office Mail Room on the date stamped hereon:

Transmittal Form (1 page) 1.

An executed Declaration for Patent Application (2 pages) 2.

This return receipt postcard 3.

Atty: Anita Varma

Mailing Date: February 11, 2002 First Class Mailing (37 CFR 1.8(a))

Appln. Serial No. 10/019,325 Filed: December 21, 2001

Atty Docket No.: <u>GDV-001.01</u>
( | \$403 - 101)

Applicants: Jeffrey I. Weitz

Heparin Compositions That Inhibit Clot Associated Coagulation Factors

The following was/were received in the U.S. Patent & Trademark Office Mail Room on the date stamped hereon:

Transmittal Form (1 page) 1.

An executed Declaration for Patent Application (2 pages) 2.

3. This return receipt postcard

Atty: Anita Varma

Mailing Date: February 11, 2002 First Class Mailing (37 CFR 1.8(a))

JC20 Rec'd PCT/PTO 2 7 FEB 2002





25181

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box FC1 United States Potent and Fraderical Office Washington, D.C., 2023

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO.

10/019,325 Jeffrey I. Weitz GDV-001.01

INTERNATIONAL APPLICATION NO

PCT/CA00/00774

Regulement LA FILING DATE

06/30/1999

5.8.02 W/ Seg Listing 06/29 2000

CONFIRMATION NO. 6259 371 FORMALITIES LETTER

\*OC00000007563450\*

PATENT GROUP ONE POST OFFICE SQUARE BOSTON, MA 02109

FOLEY, HOAG & ELIOT, LLP

Date Mailed: 03/08/2002

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b). identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
  - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- \$130 Surcharge for providing the oath or declaration later than the appropriate 30 months months from the priority date (37 CFR 1.492(e)) is required.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

MAR 1 8 2002

DATENT DEPT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
  - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832. as indicated on the attached marked-up copy of the "Raw Sequence Listing."
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
    - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
    - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For guestions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentln Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

#### SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

- \$130 Late oath or declaration Surcharge.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832. as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/019,325	PCT/CA00/00774	GDV-001.01

FORM PCT/DO/EO/905 (371 Formalities Notice)